Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:11 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Cytokinetics Clear all

Conditions: Intermittent Claudication, Peripheral Artery Disease
Interventions: Placebo, 375 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 40 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 14
States / cities: Phoenix, Arizona • Santa Ana, California • Stanford, California + 11 more

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 48
States / cities: Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Reldesemtiv, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Torrance, California • Pittsburgh, Pennsylvania

Conditions: Symptomatic Hypertrophic Cardiomyopathy (HCM)
Interventions: Aficamten (5 - 20 mg); Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 900 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 57
States / cities: Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 43 more

Conditions: Healthy Participants
Interventions: Aficamten, Aficamten-matching Placebo, Moxifloxacin; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Non-Hodgkin's Lymphoma, Hodgkin's Disease
Interventions: SB-743921; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 6
States / cities: Hackensack, New Jersey • New York, New York • Chapel Hill, North Carolina + 1 more

Conditions: Hypertrophic Cardiomyopathy (HCM)
Interventions: CK-3773274 (5 - 15 mg), CK-3773274 (10 - 30 mg), Placebo for CK-3773274; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 18
States / cities: Los Angeles, California • San Francisco, California • Evanston, Illinois + 13 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: CK-2017357, Placebo, Riluzole 50 MG; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 11
States / cities: Fresno, California • La Jolla, California • Orange, California + 8 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Tirasemtiv, Placebo tablets; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 744 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 49
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 42 more

Conditions: Healthy Participants
Interventions: CK-4021586, Placebo for CK-4021586; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Heart Failure
Interventions: Omecamtiv Mecarbil, Placebo, Standard of Care; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 8,256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 310
States / cities: Birmingham, Alabama • Fort Payne, Alabama • Huntsville, Alabama + 249 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B); Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: San Francisco, California • Jacksonville, Florida • Kansas City, Kansas + 6 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: tirasemtiv; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 41
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 36 more

Conditions: Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
Interventions: Aficamten, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 20 more

Conditions: Modified Release Oral Formulation, Left Ventricular Systolic Dysfunction, Chronic Heart Failure, History of Chronic Heart Failure, Left Ventricular Ejection Fraction, Pharmacokinetics, Echocardiogram
Interventions: Omecamtiv Mecarbil Matrix F1 Formulation, Omecamtiv Mecarbil Matrix F2 Formulation, Placebo, Omecamtiv Mecarbil Swellable Core Technology F2; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 38
States / cities: Mobile, Alabama • Costa Mesa, California • Fresno, California + 34 more

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions: Aficamten (CK-3773274) (5 mg, 10 mg, 15 mg and 20 mg), Placebo to match aficamten, Metoprolol succinate (50 mg, 100 mg, 150 mg and 200 mg), Placebo to match metoprolol succinate; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 28
States / cities: Anchorage, Alaska • Phoenix, Arizona • La Jolla, California + 21 more

Conditions: Healthy Participants
Interventions: CK-3828136, Placebo for CK-3828136; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Heart Failure
Interventions: CK-1827452; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Baltimore, Maryland • Salt Lake City, Utah

Conditions: Spinal Muscular Atrophy
Interventions: Placebo, Reldesemtiv 150 mg, Reldesemtiv 450 mg; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 12 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 15
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 12 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Placebo, 250 mg CK-2017357, 500 mg CK-2017357; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 15
States / cities: Phoenix, Arizona • Fresno, California • San Francisco, California + 12 more

Conditions: Amyotrophic Lateral Sclerosis
Interventions: Reldesemtiv, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 47
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 41 more

Conditions: Heart Failure
Interventions: Placebo, Omecamtiv mecarbil; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 45
States / cities: Mobile, Alabama • Inglewood, California • La Jolla, California + 38 more

Conditions: Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects
Interventions: CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Heart Failure
Interventions: CK-1827452, Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: San Diego, California • Newark, Delaware

Search by objective public record fields.

A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease

Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma

Dose-finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CK-3773274 in Adults With Hypertrophic Cardiomyopathy

Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year

A Single and Multiple Ascending Dose Study of CK-4021586 in Healthy Adult Participants

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Study for Patients Who Completed VITALITY-ALS (CY 4031)

A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

COSMIC-HF - Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants

Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

A Study of CK-2127107 in Patients With Spinal Muscular Atrophy

A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)

Study to Evaluate the Safety and Efficacy of IV Infusion Treatment With Omecamtiv Mecarbil in Subjects With Left Ventricular Systolic Dysfunction Hospitalized for Acute Heart Failure (ATOMIC-AHF)

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

A Study of CK-1827452 Infusion in Stable Heart Failure